In their report, Bayer investigators reported that the treatment has indicated improvement in median overall survival rate of metastatic patients by 29%, with a 6.4 month overall survival rate demonstrated in the drug arm while medial survival period of 5 months is achieved under placebo for advanced patients who had already failed standard therapy. High rates of side effects such as fatigue, skin reactions and diarrhoea is also experienced by metastatic patients in the drug arm.
Experts such as Axel Grothey, a professor of oncology at the Mayo Clinic, states that regorafenib is likely to be approved due to its novelty in the field of oncology. Bayer will be focusing its efforts next on reducing the cost of the drugs as cancer drugs have been notorius among consumers to be expensive yet marginally improves median survival of metastatic patients only.
Bayer Healthcare will be one of the major participants at the 5th annual BioPharma Asia Convention 2012. Two speakers from different fields will be speaking at Biologic Manufacturing World Asia 2012 on behalf of Bayer Healthcare namely Prof Dr Andreas Busch from Bayer Healthcare Executive Committee and Dr Berthold Boedeker, Chief Scientist from Bayer Healthcare AG. Prof Dr Andreas will be involved as one of the panel to discuss on Future Pharma – Transformation, Business Models & Innovation while Dr Berthold will be speaking about optimising biologic manufacturing operations.
Interested to find out more about Bayer Healthcare and the two speakers? Register online today to reserve your seat or contact Huisan Soh at +65 6322 2770 or email@example.com
Download our brochure here to find out more about the event!
See you at Biologic Manufacturing World Asia 2012 in March this year!